BASEL, SWITZERLAND — March 25, 2002 — Roche announced that the European Commission has granted marketing authorisation for Roche's anti-cancer medication, Xeloda (capecitabine) for the treatment of metastatic breast cancer.
The Commission granted approval for two indications, Xeloda monotherapy after failure of intensive chemotherapy, as well as the combination of Xeloda with Taxotere (docetaxel) after failure of anthracycline treatment. Xeloda/Taxotere is the first chemotherapy regimen to demonstrate significantly superior survival compared to a standard treatment of Taxotere alone in patients with metastatic breast cancer.
"The latest European approval for Xeloda is significant news for breast cancer patients and their families", said William M.Burns, Head of the Pharmaceutical Division and Member of the Executive Committee. "The outstanding study results have established Xeloda as a new treatment standard, and we believe that Xeloda can help every woman who battles with cancer at some stage of her disease. Xeloda is unique with its tumor-activated mechanism and is one of Roche's most significant new products."
Xeloda monotherapy is now approved for the treatment of patients …
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!